News

The Medicines Company announced that the European Commission has granted marketing authorization for two acute care products – Kengrexal (cangrelor) and Raplixa (sealant powder). These approvals...

ticagrelor, AstraZeneca, FDA, crushing, option

AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has approved a new administration option for acute coronary syndrome (ACS) patients who are unable to swallow ticagrelor (...

Adding the antiplatelet drug ticagrelor (Brilinta) to aspirin as long-term therapy after a heart attack significantly reduced the rate of subsequent death from cardiovascular causes, heart attack...

A novel therapy that would allow doctors to turn the body’s blood clotting ability off and on in a more controlled way was about as effective as established anticoagulants in patients undergoing...

atients with acute coronary syndrome undergoing angioplasty who received the anticoagulant drug bivalirudin did not show significant improvements in either of two coprimary endpoints — a composite...

dual antiplatelet therapy, DAPT, mortality, DES implantation, CRF, length

Data from a meta-analysis published recently in The Lancet found that extended-duration dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) implantation was associated with...

Boston Scientific, Watchman LAA device, FDA approval

Boston Scientific Corp. has received U.S. Food and Drug Administration (FDA) approval for the Watchman left atrial appendage closure device. The Watchman device offers a new stroke risk reduction...

Researchers at the University of North Carolina (UNC) School of Medicine have found the blood platelet protein Rasa3 is critical to the success of the common anti-platelet drug Plavix. Plavix...

Point of Care Decision Support, anticoagulation software, PCDS AC, therapy

Point of Care Anticoagulation software (PCDS AC) optimizes delivery of anticoagulation (AC) drugs and reduces adverse events associated with anticoagulation therapy.

atrial fibrillation, women, seniors, guidelines, blood thinners, DCRI

Nearly all women and people over 65 in the United States with atrial fibrillation are advised to take blood thinners under new guidelines based on an analysis from the Duke Clinical Research...

Xarelto, rivaroxaban, Starter Pack, FDA, deep vein thrombosis, pulmonary embolis

The U.S. Food and Drug Administration (FDA) has approved the Xarelto Starter Pack for deep vein thrombosis (DVT) and/or pulmonary embolism (PE) treatment. The starter pack was designed to help...

Patients who experienced a certain type of heart attack who received the anticoagulant fondaparinux had a lower risk of major bleeding events and death compared to patients who received low-...

nanoparticles, stroke, tPA, blood clot, magnetic, MRI, antiplatelet

By loading magnetic nanoparticles with drugs and dressing them in biochemical camouflage, Houston Methodist researchers say they can destroy blood clots 100 to 1,000 times faster than a commonly...

antiplatelet therapy, pharmaceuticals, cath lab, clinical trial, ticagrelor

AstraZeneca announced that the PEGASUS-TIMI 54 study, a large-scale outcomes trial involving more than 21,000...

rivaroxaban, Xarelto, safety performance, Janssen, NVAF

A new post-marketing study evaluating the safety of once-daily rivaroxaban (Xarelto) shows, in patients with non-valvular atrial fibrillation (NVAF), rates and patterns of major...

More than 10 percent of patients treated with aspirin therapy for primary cardiovascular disease prevention were likely inappropriately prescribed medication, according to a new study in the...

Savaysa, Daiichi Sankyo, edoxaban, FDA, approval, NVAF, thromboembolism

Daiichi Sankyo Co. Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved Savaysa (edoxaban) tablets, an oral, once-daily selective factor Xa-inhibitor, to reduce the risk of...

Discussions regarding late-breaking cardiovascular clinical trials among leading medical scientists are placing considerable emphasis on individualized patient care, particularly in the area of...

Wearable technologies, possible changes to stenting practices, state legislation on energy drinks, expanded use of minimally invasive heart repair procedures, and the development of a new class of...

The most accessed research studies in the Journal of the American College of Cardiology (JACC) in 2014 spanned many topics, including a blood test to rule out heart attack, an advisory...